Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Alphamab and 3D Medicines Choose Simcere to Market Their PD-L1 Candidate

publication date: Mar 30, 2020

Suzhou Alphamab Oncology and 3D Medicines (Beijing) will market KN035 (envafolimab), their partnered PD-L1 checkpoint inhibitor, through Simcere Pharma. Simcere will be paid a marketing fee. Alphamab discovered the candidate and will manufacturer it. 3DMed is overseeing KN035's clinical development, registration and commercialization. Simcere will market KN035 in mainland China after the product's registration. In 2016, Alphamab and 3DMed formed a co-development partnership for KN035, which is in a China Phase III trial for advanced biliary tract cancer (BTC). More details....

Stock Symbol: (HK: 9966)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.